Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study

par M.   Yu. Fedyanin, L.  Yu.  Vladimirova, V.  A.  Chubenko, L.   A. Zagorskaya, A.  V.  Belyaeva, O.  L.  Fakhrutdinova, S.  A.  Belukhin, A.   S. Zhabina, L.   V. Khalikova, L.  V.  Bolotina, R.   V. Orlova, F.  V.  Moiseenko, G.   Z. Mukhametshina, A.  I.  Khasanova, A.  V.  Belonogov, Kh.  S.  Musaeva, O.  Yu.  Novikova, I.  Yu.  Stradaeva, I.  L.  Popova, S.  P.  Erdniev, A.  K.  Ivanova, A.  V.  Androsova, P.  S.  Feoktistova, E.  S.  Kuzmina, E.   V. Karabina, O.  V.  Nekrasova, O.  V.  Sekhina, A.   A. Mishchenko, L.  A.  Mukova, B.  Kh.  Kertiev, G.  I.  Kosar, S.   N. Osodoeva, A.  I.  Kats, R.  R.  Malina, M.  A.  Lyadova, A.  A.  Tryakin, S.  A.  Tyulandin
Publié 2022-03-01

Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer

par M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, L. V. Bolotina, F. V. Moiseenko, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, V. M. Moiseenko, А. А. Meshcheryakov, E. V. Artamonova, I. A. Pokataev, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, G. Z. Mukhametshina, R. V. Orlova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, V. M. Sherstnev, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, A. A. Tryakin, S. A. Tjulandin
Publié 2019-06-01